Navigation Links
Endologix Added to Russell Indexes
Date:6/30/2009

IRVINE, Calif., June 30 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, today announced that it has been added to the Russell 3000(R), Russell 2000(R) and Russell Global Indexes, effective June 26, 2009 after the close of the U.S. markets.

John McDermott, President and CEO, said, "We are pleased that Endologix is now included in the Russell Indexes, which has $4 trillion in assets currently benchmarked to them. The addition should increase the Company's exposure to potential institutional and retail investors as we continue to roll out our new products and increase our share of the abdominal aortic aneurysm market."

The annual reconstitution of Russell's U.S. indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization. Membership in the Russell 3000, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes. The Russell 3000 also serves as the U.S. component to the Russell Global Index, which Russell launched in 2007.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $4 trillion in assets currently are benchmarked to them.

About Endologix

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink(R) System, which is an endovascular stent graft for the treatment of abdominal
'/>"/>

SOURCE Endologix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Endologix Announces Full Commercial Launch of IntuiTrak Express Delivery System
2. Endologix Receives Nasdaq Letter on Director Independence
3. Endologix Announces Live Web Cast of Presentation in SMH Capital Small Cap Spotlight on June 17, 2009 at 4:15 p.m. ET
4. Corals added to IUCN Red List of Threatened Species for first time
5. Halozyme Therapeutics Added to Nasdaq Biotech Index
6. Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
7. An Event Added to Celebrate and Empower North Carolina Women
8. Blood pressure drug may have added benefit
9. VA Has Added 20 New Vet Centers
10. Turner Investment Partners Added to AHA Diversified Equity Fund
11. Kelsey Grammer, Ben Stiller, Maroon 5 and The Roots Added to COMEDY CENTRALs(R) Live On-air Charity Special Night of Too Many Stars: An Overbooked Concert for Autism Education Hosted by Jon Stewart on Sunday April 13, at 8 p.m. ET
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Preventing lung scarring may extend lives of lung cancer patients 2Health News:Rhode Island Hospital lands $11.1M grant from National Institutes of Health 2Health News:Rhode Island Hospital lands $11.1M grant from National Institutes of Health 3Health News:Rhode Island Hospital lands $11.1M grant from National Institutes of Health 4Health News:Rhode Island Hospital lands $11.1M grant from National Institutes of Health 5Health News:Kellogg School of Management Announces 'Code Red' 2Health News:Charlie Rose Science Series to Focus on the Challenge of Researching and Implementing Effective Treatments for Diseases of the Developing World 2Health News:Charlie Rose Science Series to Focus on the Challenge of Researching and Implementing Effective Treatments for Diseases of the Developing World 3Health News:Charlie Rose Science Series to Focus on the Challenge of Researching and Implementing Effective Treatments for Diseases of the Developing World 4Health News:The Organic Trade Association Hails Preliminary Research Findings Showing Nutritional Benefits of Organic Products 2Health News:HealthShares(TM) Announces Change to the HealthShares(TM) Ophthalmology Index and the HealthShares(TM) Composite Index 2Health News:HealthShares(TM) Announces Change to the HealthShares(TM) Ophthalmology Index and the HealthShares(TM) Composite Index 3
Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 656 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 156 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 256 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 3Pelosi and Reid Invite President Obama to Address Congress 56085 1Chindex International Announces September Investor Conferences Participation 56083 1Chindex International Announces September Investor Conferences Participation 56083 2